Researchers at the Institut Pasteur have developed a vaccine that spurred the production of autoantibodies to immunoglobulin E (IgE) antibodies, protecting vaccinated mice from anaphylaxis. In their paper, which they published in Science Translational Medicine on Dec. 3, 2025, the authors noted that the polyclonal antibodies generated by their vaccine lasted “for up to 12 months postvaccination with a similar avidity as the approved anti-IgE mAb omalizumab [Xolair, Roche AG].”
Hypoxic pulmonary hypertension (HPH) is a condition characterized by increased pulmonary artery pressure caused by prolonged exposure to a hypoxic environment. It frequently occurs among individuals residing at high altitudes and those with chronic obstructive pulmonary disease.
Boehringer Ingelheim Pharma GmbH & Co. KG has described cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors reported to be useful for the treatment of autoinflammatory interferonopathy, idiopathic pulmonary fibrosis, cirrhosis, metabolic dysfunction-associated steatohepatitis (MASH), interstitial lung diseases, systemic scleroderma (systemic sclerosis) and systemic lupus erythematosus.
A team of investigators at the University of Pittsburgh have found that a CXCR3-activating peptide (named CXCL10p) can prevent lung fibrosis and inflammation in the bleomycin mouse model.
Suzhou Junjian Yifang Biopharmaceutical Co. Ltd. has described pyrimido[6,1-a]isoquinolin-4-one derivatives acting as dual phosphodiesterase PDE3 and PDE4 inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease.
Cystic fibrosis (CF) is a genetic disorder affecting around 90,000 people worldwide. It is commonly caused by the ΔF508 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which results in a misfolded CFTR protein that is subsequently ubiquitinated and degraded.
Montse Rosa Therapeutics Inc. has developed a molecular glue degrader named MRT-2359 that selectively degrades the translation termination factor ERF3A.
Carbon Biosciences Inc. has presented data on a parvovirus-based vector that restores full-length cystic fibrosis transmembrane conductance regulator (CFTR) gene for treating cystic fibrosis.
Researchers at Calluna Pharma AS, Agiana Pharmaceuticals AS and Roskilde University have developed the first humanized IgG4 antibody that inhibits S100A4, which is a calcium-binding protein that helps drive fibrotic inflammatory diseases.
Insmed Inc. has described cathepsin C (dipeptidyl peptidase I; DPP-1) inhibitors reported to be useful for the treatment of cancer, liver injury, osteoarthritis, heart failure, inflammatory bowel disease, rheumatoid arthritis, bronchiectasis and chronic obstructive pulmonary disease, among others.
RSS
